Seattle Genetics & Astellas bag accelerated approval for PADCEV™
Category: #health  By Mateen Dalal  Date: 2019-12-20
  • share
  • Twitter
  • Facebook
  • LinkedIn

Seattle Genetics & Astellas bag accelerated approval for PADCEV™

Seattle Genetics, Inc., a biotechnology company based in U.S., and Astellas Pharma Inc. have recently revealed that the U.S. Food and Drug Administration (FDA) has given PADCEV™ an accelerated approval for treating adult patients with metastatic or locally advanced urothelial cancer. It would be given to patients that have gone through platinum-containing chemotherapy and a PD-1/L1 inhibitor in the past.

According to reliable sources, the remarkable tumor response rate of PADCEV has led to its approval under the FDA’s Accelerated Approval Program. Continued approval would still be subject to the drug’s description and verification of clinical benefit in confirmatory studies.

Apparnetly, PADCEV would be the first-ever treatment to be approved by the FDA in the U.S for advanced urothelial cancer patients . It is a novel ADC (antibody-drug conjugate) that is formulated against Nectin-4, a protein found on top of cells and is highly expressed in bladder cancer.

According to Roger Dansey, M.D., Chief Medical Officer, Seattle Genetics, PADCEV marks as the first approved ADC for patients suffering from urothelial cancer. This approval is a result of the innovative work that both the company has done on this technology.

Prior to this news, Seattle Genetics had made headlines when it bagged approval for ADCETRIS® in the supplemental New Drug Submission from Health Canada. As per the approval, ADCETRIS would be used in combination with CHP chemotherapy for the treatment of untreated PTCL (peripheral T-cell lymphoma)-NOS (not otherwise specified), angioimmunoblastic T-cell lymphoma (AITL) or sALCL (systemic anaplastic large cell lymphoma) in adult patients whose tumors express CD30.

Commenting on which, Dansey said that with this new indication for ADCETRIS, eligible patients and physicians in Canada can have access to this drug for treating frontline CD30-expressing PTCL, a key milestone supporting the firms vision to continue expanding ADCETRIS globally.

Source Credit: https://investor.seattlegenetics.com/press-releases/news-details/2019/FDA-Grants-Accelerated-Approval-to-Astellas-and-Seattle-Genetics-PADCEV-enfortumab-vedotin-ejfv-for-People-with-Locally-Advanced-or-Metastatic-Urothelial-Cancer-the-Most-Common-Type-of-Bladder-Cancer/default.aspx

 

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

Alphabet’s Google to face lawsuit from NLRB for violating labor laws
Alphabet’s Google to face lawsuit from NLRB for violating labor laws
By Mateen Dalal

In a recent turn of events, U.S. government body National Labor Relations Board (NLRB) has reportedly issued a complaint against American multinational technology company, Google LLC for unlawfully monitoring as well as questioning its workers and su...

Britain’s CMA to levy tougher competition rules on Google and Facebook
Britain’s CMA to levy tougher competition rules on Google and Facebook
By Mateen Dalal

Facebook and Google accounted for around 80% of the total 14 billion pounds spent on digital advertising in 2019. MOW has reportedly accused Google of modifying its Chromium developer tools and Chrome browser to get greater control over advertiser...

Amazon, U.S. Government team up to prevent sale of counterfeit goods
Amazon, U.S. Government team up to prevent sale of counterfeit goods
By Mateen Dalal

According to reliable sources, Washington-headquartered American multinational technology company, Amazon.com Inc has reportedly initiated a joint venture with the U.S. government’s counterfeit agency, the IPR Center (National Intellectual Prop...